Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Uveal Melanoma Overview | 9 | 1 |
| Therapeutics Development | 10 | 2 |
| Pipeline Products for Uveal Melanoma Overview | 10 | 1 |
| Pipeline Products for Uveal Melanoma Comparative Analysis | 11 | 1 |
| Uveal Melanoma Therapeutics under Development by Companies | 12 | 1 |
| Uveal Melanoma Therapeutics under Investigation by Universities/Institutes | 13 | 1 |
| Uveal Melanoma Pipeline Products Glance | 14 | 3 |
| Late Stage Products | 14 | 1 |
| Clinical Stage Products | 15 | 1 |
| Early Stage Products | 16 | 1 |
| Uveal Melanoma Products under Development by Companies | 17 | 1 |
| Uveal Melanoma Products under Investigation by Universities/Institutes | 18 | 1 |
| Uveal Melanoma Companies Involved in Therapeutics Development | 19 | 12 |
| Aura Biosciences, Inc. | 19 | 1 |
| Bellicum Pharmaceuticals, Inc. | 20 | 1 |
| Celldex Therapeutics, Inc. | 21 | 1 |
| Cleveland BioLabs, Inc. | 22 | 1 |
| Eli Lilly and Company | 23 | 1 |
| Iconic Therapeutics, Inc. | 24 | 1 |
| Immunocore Limited | 25 | 1 |
| Navigen Pharmaceuticals, Inc. | 26 | 1 |
| Novartis AG | 27 | 1 |
| PEP-Therapy SAS | 28 | 1 |
| Pfizer Inc. | 29 | 1 |
| Spectrum Pharmaceuticals, Inc. | 30 | 1 |
| Uveal Melanoma Therapeutics Assessment | 31 | 11 |
| Assessment by Monotherapy Products | 31 | 1 |
| Assessment by Target | 32 | 3 |
| Assessment by Mechanism of Action | 35 | 3 |
| Assessment by Route of Administration | 38 | 2 |
| Assessment by Molecule Type | 40 | 2 |
| Drug Profiles | 42 | 58 |
| alpelisib Drug Profile | 42 | 3 |
| AU-011 Drug Profile | 45 | 1 |
| BPX-701 Drug Profile | 46 | 1 |
| Cellular Immunotherapy to Target Melan-A, MAGE-3 and Survivin for Melanoma and Uveal Melanoma Drug Profile | 47 | 1 |
| crizotinib Drug Profile | 48 | 7 |
| DPTC-9h Drug Profile | 55 | 1 |
| emibetuzumab Drug Profile | 56 | 2 |
| entolimod Drug Profile | 58 | 7 |
| glembatumumab vedotin Drug Profile | 65 | 4 |
| hI-con1 Drug Profile | 69 | 2 |
| HPH-196 Drug Profile | 71 | 1 |
| HPH-211 Drug Profile | 72 | 1 |
| IMCgp-100 Drug Profile | 73 | 3 |
| KCN-1 Drug Profile | 76 | 1 |
| LXS-196 Drug Profile | 77 | 1 |
| merestinib Drug Profile | 78 | 2 |
| NAV-2729 Drug Profile | 80 | 2 |
| nutlin-3 Drug Profile | 82 | 1 |
| pasireotide ER Drug Profile | 83 | 3 |
| sotrastaurin acetate Drug Profile | 86 | 2 |
| sunitinib malate Drug Profile | 88 | 5 |
| Vaccine 2 for Melanoma Drug Profile | 93 | 1 |
| Vaccine for Oncology Drug Profile | 94 | 1 |
| vincristine sulfate Drug Profile | 95 | 5 |
| Uveal Melanoma Dormant Projects | 100 | 1 |
| Uveal Melanoma Discontinued Products | 101 | 1 |
| Uveal Melanoma Product Development Milestones | 102 | 5 |
| Featured News &Press Releases | 102 | 1 |
| Apr 18, 2016: Celldex Therapeutics Presents data on Glembatumumab Vedotin at AACR 2016 | 102 | 1 |
| Mar 30, 2016: Immunocore s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma | 102 | 1 |
| Jan 25, 2016: Immunocore s IMCgp100 Granted Orphan Drug Designation by US FDA for the Treatment of Uveal Melanoma | 103 | 1 |
| Jan 11, 2016: Bellicum Pharmaceuticals Announces Submission of BPX-701 Clinical Trial Protocols for Review by the NIH RAC | 103 | 1 |
| Sep 09, 2015: Immunocore s IMCgp100 Accepted for Adaptive Pathway Pilot Programme | 104 | 1 |
| Jun 29, 2015: Lilly and Immunocore To Conduct Phase Ib/II Clinical Trial Collaboration For Treatment Of uveal melanoma | 104 | 1 |
| May 21, 2015: FDA Grants Orphan Drug Designation to Aura Biosciences Novel Treatment for Uveal Melanoma | 105 | 2 |
| Appendix | 107 | 2 |
| Methodology | 107 | 1 |
| Coverage | 107 | 1 |
| Secondary Research | 107 | 1 |
| Primary Research | 107 | 1 |
| Expert Panel Validation | 107 | 1 |
| Contact Us | 107 | 1 |
| Disclaimer | 108 | 1 |